Immunovant, Inc. (IMVT) — Net Income
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2026 | -$505.61M | -22.2% |
| 2025 | -$413.84M | -59.6% |
| 2024 | -$259.34M | -22.9% |
| 2023 | -$210.96M | -34.6% |
| 2022 | -$156.73M | -45.9% |
| 2021 | -$107.43M | -61.8% |
| 2020 | -$66.39M | -132.1% |
| 2019 | -$28.60M | — |
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2026 | -$505.61M | -22.2% |
| 2025 | -$413.84M | -59.6% |
| 2024 | -$259.34M | -22.9% |
| 2023 | -$210.96M | -34.6% |
| 2022 | -$156.73M | -45.9% |
| 2021 | -$107.43M | -61.8% |
| 2020 | -$66.39M | -132.1% |
| 2019 | -$28.60M | — |